Are Poor Financial Prospects Dragging Down Sino Biological,Inc. (SZSE:301047 Stock?
Are Poor Financial Prospects Dragging Down Sino Biological,Inc. (SZSE:301047 Stock?
Sino BiologicalInc (SZSE:301047) has had a rough three months with its share price down 10%. To decide if this trend could continue, we decided to look at its weak fundamentals as they shape the long-term market trends. Particularly, we will be paying attention to Sino BiologicalInc's ROE today.
中国生物股份有限公司(SZSE:301047)经历了艰难的三个月,股价下跌了10%。为了确定这一趋势是否会继续下去,我们决定看看其疲软的基本面,因为它们塑造了长期的市场趋势。尤其是,我们今天将关注中国生物股份有限公司的净资产收益率。
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.
股本回报率或净资产收益率是股东要考虑的一个重要因素,因为它告诉他们他们的资本再投资的效率。换句话说,这是一个衡量公司股东提供的资本回报率的盈利比率。
Check out our latest analysis for Sino BiologicalInc
查看我们对中国生物股份有限公司的最新分析
How Is ROE Calculated?
净资产收益率是如何计算的?
ROE can be calculated by using the formula:
可使用以下公式计算净资产收益率:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率=(持续经营的)净利润?股东权益
So, based on the above formula, the ROE for Sino BiologicalInc is:
因此,根据上述公式,中国生物股份有限公司的净资产收益率为:
4.0% = CN¥247m ÷ CN¥6.2b (Based on the trailing twelve months to June 2023).
4.0%=2.47亿元×62亿元(以截至2023年6月的12个月为基础)。
The 'return' is the income the business earned over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.04 in profit.
“回报”指的是企业在过去一年中获得的收入。这意味着,股东权益每增加1元,公司就会产生0.04元的利润。
Why Is ROE Important For Earnings Growth?
为什么净资产收益率对收益增长很重要?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我们已经证实,净资产收益率是一家公司未来收益的有效盈利指标。根据公司选择再投资或“保留”多少利润,我们就能够评估一家公司未来产生利润的能力。假设其他条件相同,与没有相同特征的公司相比,拥有更高股本回报率和更高利润保留率的公司通常会有更高的增长率。
Sino BiologicalInc's Earnings Growth And 4.0% ROE
中国生物股份有限公司盈利增长和4.0%的净资产收益率
It is quite clear that Sino BiologicalInc's ROE is rather low. Not just that, even compared to the industry average of 6.7%, the company's ROE is entirely unremarkable. As a result, Sino BiologicalInc's flat earnings over the past five years doesn't come as a surprise given its lower ROE.
很明显,中国生物股份有限公司的净资产收益率相当低。不仅如此,即使与6.7%的行业平均水平相比,该公司的净资产收益率也完全不起眼。因此,鉴于中国生物股份有限公司的净资产收益率(ROE)较低,过去五年的收益持平并不令人意外。
We then compared Sino BiologicalInc's net income growth with the industry and found that the average industry growth rate was 13% in the same 5-year period.
然后,我们将中国生物股份有限公司的净收入增长与行业进行了比较,发现在同一5年期间,行业的平均增长率为13%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231022/0-d81e2d06be11e2d6f9052100dfb13985-0-4f8b9ba2e278f62fa396daa15727b5ea.png/big)
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about Sino BiologicalInc's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
盈利增长是股票估值的一个重要因素。投资者应该尝试确定预期的收益增长或下降是否已计入价格,无论是哪种情况。这样做将有助于他们确定该股的未来看起来是光明的还是不祥的。如果你想知道中国生物股份有限公司的估值,看看这个衡量其市盈率的指标,与其行业相比。
Is Sino BiologicalInc Making Efficient Use Of Its Profits?
中国生物科技股份有限公司是否在有效利用其利润?
Sino BiologicalInc has a three-year median payout ratio as high as 105% meaning that the company is paying a dividend which is beyond its means. The absence in growth is therefore not surprising. Its usually very hard to sustain dividend payments that are higher than reported profits. That's a huge risk in our books. To know the 3 risks we have identified for Sino BiologicalInc visit our risks dashboard for free.
中国生物股份有限公司的三年派息率中值高达105%,这意味着该公司支付的股息超出了其能力范围。因此,增长乏力并不令人意外。通常很难维持高于公布利润的股息支付。在我们的账簿上,这是一个巨大的风险。要了解我们为中国生物股份有限公司确定的3个风险,请免费访问我们的风险仪表板。
Additionally, Sino BiologicalInc started paying a dividend only recently. So it looks like the management must have perceived that shareholders favor dividends over earnings growth.
此外,中国生物股份有限公司最近才开始派发股息。因此,看起来管理层肯定已经意识到,股东更喜欢分红,而不是收益增长。
Conclusion
结论
On the whole, Sino BiologicalInc's performance is quite a big let-down. Particularly, its ROE is a huge disappointment, not to mention its lack of proper reinvestment into the business. As a result its earnings growth has also been quite disappointing. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
总体而言,中国生物股份有限公司的表现相当令人失望。特别是,它的净资产收益率令人大失所望,更不用说它缺乏对业务的适当再投资了。因此,它的收益增长也相当令人失望。话虽如此,我们研究了最新的分析师预测,发现尽管该公司过去的收益有所缩水,但分析师预计其未来的收益将会增长。这些分析师的预期是基于对该行业的广泛预期,还是基于该公司的基本面?点击此处进入我们分析师对该公司的预测页面。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。